Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...

A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans at risk for kidney failure.

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Report with the AI impact on market trends - The global biotech market size is estimated to grow by USD 805.6 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR ...

With thousands of press releases published each week, it can be difficult to keep up with everything on . To help journalists ...

Infant mortality in the has increased by 7% since the 2022 Supreme Court decision overturned the constitutional right to ...

SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...

Eyeing an expected leap in demand for contrast media—used in X-rays, CT scans and more—GE HealthCare is upping its stake in the Emerald Isle. | GE HealthCare is pumping $138 million into its ...